Minerva Neurosciences (NERV) Change in Accured Expenses (2013 - 2026)
Minerva Neurosciences posted quarterly Change in Accured Expenses of $796544.0 for Q1 2026, up 918.3% year-on-year from $78223.0 in Q1 2025, and up 646.07% on a QoQ basis from -$145868.0 in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Change in Accured Expenses data on file, last reported at $796544.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 918.3% year-over-year to $796544.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 1276.95% YoY), and the FY2025 full-year result was $317446.0, up 203.71% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $796544.0, up from -$145868.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.0 million in Q2 2024 and bottomed at -$2.7 million in Q4 2024.
- The 5-year median for Change in Accured Expenses is $78223.0 (2025), against an average of $81014.8.
- Peak annual rise in Change in Accured Expenses reached 2773.82% in 2024, while the deepest fall reached 543.84% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$1.3 million in 2022, then jumped by 66.6% to -$419493.0 in 2023, then plunged by 543.84% to -$2.7 million in 2024, then surged by 94.6% to -$145868.0 in 2025, then jumped by 646.07% to $796544.0 in 2026.
- The last three Change in Accured Expenses figures came in at $796544.0 (Q1 2026), -$145868.0 (Q4 2025), and $60255.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 796,544.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 796,544.00 |
| Mar 31, 2026 | 796,544.00 |
| Dec 31, 2025 | -145,868.00 |
| Dec 31, 2025 | -145,868.00 |
| Sep 30, 2025 | 60,255.00 |
| Sep 30, 2025 | 60,255.00 |
| Jun 30, 2025 | 324,836.00 |
| Jun 30, 2025 | 324,836.00 |
| Mar 31, 2025 | 78,223.00 |
| Mar 31, 2025 | 78,223.00 |
| Dec 31, 2024 | -2.70 Mn |
| Dec 31, 2024 | -2.70 Mn |
| Sep 30, 2024 | 554,787.00 |
| Sep 30, 2024 | 554,787.00 |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | -139,870.00 |
| Mar 31, 2024 | -139,870.00 |
| Dec 31, 2023 | -419,493.00 |
| Dec 31, 2023 | -419,493.00 |
| Sep 30, 2023 | 345,035.00 |
| Sep 30, 2023 | 345,035.00 |
| Jun 30, 2023 | 68,892.00 |
| Jun 30, 2023 | 68,892.00 |
| Mar 31, 2023 | 1.13 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | -1.26 Mn |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -225,228.00 |
| Sep 30, 2022 | -225,228.00 |
| Jun 30, 2022 | 227,681.00 |
| Jun 30, 2022 | 227,681.00 |
| Mar 31, 2022 | 695,779.00 |
| Mar 31, 2022 | 695,779.00 |
| Dec 31, 2021 | -916,512.00 |
| Dec 31, 2021 | -916,512.00 |
| Sep 30, 2021 | -952,174.00 |
| Sep 30, 2021 | -952,174.00 |
| Jun 30, 2021 | 669,768.00 |
| Jun 30, 2021 | 669,768.00 |
| Mar 31, 2021 | 111,248.00 |
| Mar 31, 2021 | 111,248.00 |
| Dec 31, 2020 | -2.48 Mn |
| Dec 31, 2020 | -2.48 Mn |
| Sep 30, 2020 | 456,261.00 |
| Sep 30, 2020 | 456,261.00 |
| Jun 30, 2020 | 143,416.00 |
| Jun 30, 2020 | 143,416.00 |
| Mar 31, 2020 | -202,930.00 |
| Mar 31, 2020 | -202,930.00 |
| Dec 31, 2019 | -259,187.00 |
| Dec 31, 2019 | -259,187.00 |
| Sep 30, 2019 | -87,255.00 |
| Sep 30, 2019 | -87,255.00 |
| Jun 30, 2019 | 764,650.00 |
| Jun 30, 2019 | 764,650.00 |
| Mar 31, 2019 | 1.91 Mn |
| Mar 31, 2019 | 1.91 Mn |
| Dec 31, 2018 | -1.19 Mn |
| Dec 31, 2018 | -1.19 Mn |
| Sep 30, 2018 | 684,053.00 |
| Sep 30, 2018 | 684,053.00 |
| Jun 30, 2018 | -81,106.00 |
| Jun 30, 2018 | -81,106.00 |
| Mar 31, 2018 | 952,720.00 |
| Mar 31, 2018 | 952,720.00 |
| Dec 31, 2017 | -582,557.00 |
| Dec 31, 2017 | -582,557.00 |
| Sep 30, 2017 | 746,966.00 |
| Sep 30, 2017 | 746,966.00 |
| Jun 30, 2017 | -397,945.00 |
| Jun 30, 2017 | -397,945.00 |
| Mar 31, 2017 | 857,571.00 |
| Mar 31, 2017 | 857,571.00 |
| Dec 31, 2016 | -165,042.00 |
| Dec 31, 2016 | -165,042.00 |
| Sep 30, 2016 | -472,346.00 |
| Sep 30, 2016 | -472,346.00 |
| Jun 30, 2016 | -1.65 Mn |
| Jun 30, 2016 | -1.65 Mn |
| Mar 31, 2016 | 577,238.00 |
| Mar 31, 2016 | 577,238.00 |
| Dec 31, 2015 | 300,007.00 |
| Dec 31, 2015 | 300,007.00 |
| Sep 30, 2015 | 723,578.00 |
| Sep 30, 2015 | 723,578.00 |
| Jun 30, 2015 | -383,127.00 |
| Jun 30, 2015 | -383,127.00 |
| Mar 31, 2015 | 238,922.00 |
| Mar 31, 2015 | 238,922.00 |
| Dec 31, 2014 | 794,834.00 |
| Dec 31, 2014 | 794,834.00 |
| Sep 30, 2014 | -1.20 Mn |
| Sep 30, 2014 | -1.20 Mn |
| Jun 30, 2014 | 580,633.00 |
| Jun 30, 2014 | 580,633.00 |
| Mar 31, 2014 | -60,424.00 |
| Mar 31, 2014 | -60,424.00 |
| Dec 31, 2013 | -324,391.00 |
| Dec 31, 2013 | -324,391.00 |
| Sep 30, 2013 | 101,991.00 |
| Sep 30, 2013 | 101,991.00 |